Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Haleon plc (HLNCF)
Weybridge, SU, GB
Haleon plc operates as a global consumer healthcare enterprise, actively involved in the research, development, production, and distribution of a diverse range of products. Its business activities cover extensive regions, including North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company offers various solutions such as oral hygiene products, pain management remedies, respiratory care items, digestive health aids, and a selection of vitamins, minerals, and supplements. Its notable brand collection features Panadol, Voltaren, Advil, Otrivin, Theraflu, Sensodyne, Polident, parodontax, and Centrum. Established in 2021, the company was initially named DRVW 2022 plc before officially rebranding to Haleon plc in February 2022. Its main office is situated in Brentford, United Kingdom.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -5.00% | -1.51% | -4.00% | -12.64% | -6.56% | -8.80% | -17.09% | +14.00% | +31.03% | +31.03% | +31.03% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
-
Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%-1.8% Q2'25: -1.3% (vs Q2'24)
-
EPS growth Drug Manufacturers - Specialty & Generic: +16.5%+18.8% ★ Q2'25: +35.3% (vs Q2'24)
-
FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%+17.7% Q2'25: +17.0% (vs Q2'24)
-
EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%+22.4% ★ Q2'25: +22.2% (vs Q2'24)
-
ROIC Drug Manufacturers - Specialty & Generic: +6.5%+8.1% ★ Q2'25: +7.8% (vs Q2'24)
-
Share dilution Drug Manufacturers - Specialty & Generic: +0.0%-1.9% ★ Q2'25: -1.6% (vs Q2'24)
-
Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×3.04× Q2'25: 3.08× (vs Q2'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 16 Rev. Ana. 1 EPS Ana. |
Dec 2027 16 Rev. Ana. 1 EPS Ana. |
Dec 2028 14 Rev. Ana. 1 EPS Ana. |
Dec 2029 15 Rev. Ana. 1 EPS Ana. |
Dec 2030 15 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|---|---|---|
| Revenue |
10.86B
est: 13.11B (-17.2%)
|
11.30B
est: 14.37B (-21.3%)
|
11.23B
est: 11.21B (+0.2%)
|
11.03B
est: 11.07B (-0.4%)
|
11.59B
11.51B – 11.69B
+4.7% YoY
|
12.09B
11.92B – 12.35B
+4.3% YoY
|
12.61B
12.48B – 12.80B
+4.3% YoY
|
13.14B
13.00B – 13.34B
+4.2% YoY
|
13.57B
13.43B – 13.78B
+3.3% YoY
|
| EBITDA |
2.18B
est: 2.80B (-22.0%)
|
2.35B
est: 3.07B (-23.4%)
|
2.63B
est: 3.32B (-21.0%)
|
2.83B
est: 3.28B (-13.7%)
|
3.44B
3.41B – 3.47B
+4.7% YoY
|
3.58B
3.54B – 3.66B
+4.3% YoY
|
3.74B
3.70B – 3.80B
+4.3% YoY
|
3.90B
3.86B – 3.96B
+4.2% YoY
|
4.02B
3.98B – 4.09B
+3.3% YoY
|
| EBIT |
1.90B
est: 2.43B (-21.9%)
|
2.04B
est: 2.66B (-23.3%)
|
2.30B
est: 2.90B (-20.6%)
|
2.47B
est: 2.87B (-13.6%)
|
3.00B
2.98B – 3.03B
+4.7% YoY
|
3.13B
3.09B – 3.20B
+4.3% YoY
|
3.26B
3.23B – 3.31B
+4.3% YoY
|
3.40B
3.36B – 3.45B
+4.2% YoY
|
3.51B
3.48B – 3.57B
+3.3% YoY
|
| Net Income |
1.06B
est: 1.69B (-37.3%)
|
1.05B
est: 1.64B (-35.9%)
|
1.44B
est: 1.58B (-8.8%)
|
1.67B
est: 1.67B (-0.5%)
|
1.89B
1.86B – 1.93B
+12.8% YoY
|
2.07B
2.04B – 2.11B
+9.5% YoY
|
2.26B
2.23B – 2.31B
+9.4% YoY
|
2.46B
2.43B – 2.51B
+8.9% YoY
|
2.54B
2.51B – 2.60B
+3.3% YoY
|
| SGA |
4.04B
est: 5.17B (-21.9%)
|
4.29B
est: 5.66B (-24.3%)
|
4.45B
est: 4.35B (+2.4%)
|
4.35B
est: 4.30B (+1.3%)
|
4.50B
4.46B – 4.54B
+4.7% YoY
|
4.69B
4.63B – 4.79B
+4.3% YoY
|
4.89B
4.84B – 4.97B
+4.3% YoY
|
5.10B
5.04B – 5.18B
+4.2% YoY
|
5.26B
5.21B – 5.35B
+3.3% YoY
|
| EPS |
0.11
est: 0.18 (-40.3%)
|
0.11
est: 0.18 (-38.3%)
|
0.16
est: 0.18 (-8.9%)
|
0.19
est: 0.19 (+2.3%)
|
0.21
0.21 – 0.21
+12.8% YoY
|
0.23
0.23 – 0.23
+9.5% YoY
|
0.25
0.25 – 0.26
+9.4% YoY
|
0.27
0.27 – 0.28
+8.9% YoY
|
0.28
0.28 – 0.29
+3.3% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-26 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-19 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-18 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-15 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-14 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-13 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-11 | C | 2/5 | 5/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-05-08 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-07 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-06 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-05 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-04 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-01 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-30 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-28 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-24 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-23 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-22 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-21 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-20 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-17 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-16 | C | 2/5 | 5/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ”) | 2.96B | 32.00% | 2.96B | — | 2.96B | 10.00 | CO | Delaware | 2023-10-10 | ↗ |
| 2 | GSK plc | 1.20B | 12.94% | 502.73M | 1.20B | 502.73M | 1.20B | CO | England and Wales | 2022-07-27 | ↗ |
| 3 | BlackRock, Inc. | 544.91M | 6.00% | 488.23M | — | 544.91M | — | HC | Delaware | 2024-11-08 | ↗ |
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Brian James McNamara | Chief Executive Officer & Executive Director | 4M | male |
| Dawn Amanda Allen | Chief Financial Officer & Director | 2M | female |
| Claire Dickson | Chief Digital & Technology Officer | — | female |
| Filippo Lanzi | President of EMEA & LatAm | — | male |
| Joanne Russell | Head of Investor Relations | — | female |
| Keith Choy | President of Asia Pacific | — | male |
| Line De Decker | Chief Human Resources Officer | — | female |
| Namrata Patel | Chief Supply Chain Officer | — | female |
| Adrian Charles Morris | General Counsel | — | male |
| Tamara Rogers | Chief Marketing Officer | — | female |
| Bjorn Timelin | Head of Strategy | — | male |
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for HLNCF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
